CN114699380A - Etodolac tablet and preparation method thereof - Google Patents
Etodolac tablet and preparation method thereof Download PDFInfo
- Publication number
- CN114699380A CN114699380A CN202111617427.2A CN202111617427A CN114699380A CN 114699380 A CN114699380 A CN 114699380A CN 202111617427 A CN202111617427 A CN 202111617427A CN 114699380 A CN114699380 A CN 114699380A
- Authority
- CN
- China
- Prior art keywords
- etodolac
- tablet
- tablets
- mixing
- granulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 229960005293 etodolac Drugs 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000000576 coating method Methods 0.000 claims abstract description 19
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 239000000853 adhesive Substances 0.000 claims abstract description 7
- 230000001070 adhesive effect Effects 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000005469 granulation Methods 0.000 claims description 19
- 230000003179 granulation Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 11
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- 229940099112 cornstarch Drugs 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960001021 lactose monohydrate Drugs 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 27
- 238000004090 dissolution Methods 0.000 abstract description 15
- 230000008859 change Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 7
- 201000008482 osteoarthritis Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000006399 behavior Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000013112 stability test Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 238000005550 wet granulation Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
Abstract
The invention provides an etodolac tablet, which comprises etodolac, a filler, an adhesive, a disintegrating agent, a lubricant and a coating material, and the etodolac tablet comprises the following components in percentage by mass: 50-75% of etodolac, 10-40% of filler, 3-10% of adhesive, 2-8% of disintegrating agent, 0.5-3% of lubricant and 1-5% of coating material. The etodolac tablet realizes good fitting with a dissolution curve of a commercially available preparation in a medium with the pH of 6.8, and the in vitro dissolution behaviors of the etodolac tablet and the commercially available preparation are similar; after the stability test of the etodolac tablet is accelerated for 6 months and carried out for 18 months for a long time, the characters, the dissolution rates, the contents and related substances have no obvious change, which shows that the stability of the etodolac tablet is good; etodolac tablets are significantly superior to commercially available etodolac tablets in treating pain and inflammation associated with osteoarthritis in pet dogs.
Description
Technical Field
The invention relates to an etodolac tablet and a preparation method thereof.
Background
The etodolac tablet has a definite therapeutic effect on pain and inflammation related to osteoarthritis of the pet dog, and can quickly relieve discomfort of the pet dog. Etodolac is an effective non-steroidal anti-inflammatory drug, belongs to indoleacetic acids, has strong analgesic effect, is widely used for treating postoperative pain, relieves the symptoms of rheumatoid arthritis and osteoarthritis, and delays osteopathic change caused by arthritis. The medicine has high safety, and rarely causes gastrointestinal adverse reaction and renal function damage common in common non-steroidal anti-inflammatory drugs.
Etodolac is different from other non-steroidal anti-inflammatory drugs, and has a tetrahydropyran mother ring, so that the good pharmacological effect is maintained, and the side effect is reduced. The mechanism of action of non-steroidal anti-inflammatory drugs is to control inflammation and relieve pain by inhibiting COX activity, reducing prostaglandin E2 production. COX is a key catalytic enzyme for the conversion of arachidonic acid to prostaglandin E2, and it has two isoenzymes (COX-1, COX-2). COX-1 is mainly used for promoting physiological prostaglandin synthesis at gastrointestinal tract, kidney and platelet, and protecting gastrointestinal mucosa; COX-2 is mainly used to promote the synthesis of prostaglandins at arthritis, and has anti-inflammatory and analgesic effects. The gastrointestinal toxicity of non-steroidal anti-inflammatory drugs is associated with COX-2 selectivity. Etodolac has the advantages of higher and proper COX-2 selectivity, little influence on COX-1 in a therapeutic dose, and protection of gastrointestinal mucosa while exerting a strong anti-inflammatory effect; another advantage of this is the protective effect on the chondrocytes.
At present, the pet market has fewer medicines for treating related pain and inflammation caused by osteoarthritis of pet dogs, and most of the products have the defects of low medicine release stability effect, high irritation to gastrointestinal tracts, low bioavailability, inconvenience in packaging, transportation and storage, complex preparation method and the like.
Disclosure of Invention
The invention aims to overcome the defects in the prior art, provides an etodolac tablet and a preparation method thereof, and solves the problems of low drug release stability effect, large irritation to gastrointestinal tracts, low bioavailability, inconvenience in packaging, transportation and storage, complex preparation method and the like of most products.
In order to solve the technical problems, the invention adopts the technical scheme that: an etodolac tablet comprises etodolac, a filling agent, a binder, a disintegrating agent, a lubricant and a coating material, and the etodolac tablet comprises the following components in percentage by mass:
further, the filler is one or a mixture of more of lactose monohydrate, microcrystalline cellulose or corn starch.
Further, the adhesive is one or a combination of several of hydroxypropyl cellulose, hydroxypropyl methylcellulose or povidone.
Further, the disintegrating agent is one or a mixture of more of croscarmellose sodium, carboxymethyl starch sodium and carboxymethyl cellulose calcium.
Further, the lubricant is one or a combination of more of talcum powder, magnesium stearate or colloidal silicon dioxide.
Further, the composition comprises, by mass, 75% of etodolac, 13% of microcrystalline cellulose, 5% of hydroxypropyl cellulose, 3% of croscarmellose sodium, 1% of magnesium stearate and 3% of opadry.
Further, the preparation method of the etodolac tablet comprises the following steps: primarily mixing etodolac, a filler and an adhesive for granulation, screening and finishing granules step by step, mixing a disintegrating agent and a lubricant, pressing the mixture into tablets, and finishing a coating process by a coating material to obtain the etodolac tablets.
Further, in the primary mixing process, the stirring speed is set to be 5r/s, the chopping speed is set to be 20r/s, then the mixture is mixed for 10min, and after the mixture is uniformly mixed, purified water is added for granulation for 5 min.
Further, the screening process is specifically as follows, wet and whole granules are taken by a 20-mesh sieve, then the drying process is carried out, and the whole granules are taken by a 24-mesh sieve, and the moisture content is less than 3%.
Further, the hardness of the etodolac tablet is 8-12 kg.
Compared with the prior art, the invention has the beneficial effects that:
1) the etodolac tablet realizes good fitting with a dissolution curve of a commercially available preparation in a medium with the pH of 6.8, and the dissolution curves of the etodolac tablet and the commercially available preparation are similar;
2) after stability investigation of the etodolac tablet accelerated for 6 months and for a long time of 18 months, the characters, the dissolution degree, the content and related substances have no obvious change, which shows that the etodolac tablet has good stability;
3) the etodolac tablet provided by the invention is remarkably superior to a commercially available etodolac tablet group in the effect of treating related pain and inflammation caused by osteoarthritis of pet dogs.
Drawings
The disclosure of the present invention is illustrated with reference to the accompanying drawings. It is to be understood that the drawings are designed solely for the purposes of illustration and not as a definition of the limits of the invention. In the drawings, like reference numerals are used to refer to like parts. Wherein:
FIG. 1 is a dissolution profile of etodolac tablets and commercial formulations prepared according to the methods of examples 1-8 of the present invention.
Detailed Description
It is easily understood that the technical solution according to the present invention can be provided with various alternative structures and implementations by those skilled in the art without changing the spirit of the present invention. Therefore, the following detailed description and the accompanying drawings are merely illustrative of the technical aspects of the present invention, and should not be construed as limiting or restricting the technical aspects of the present invention.
An embodiment according to the present invention is shown in connection with fig. 1. An etodolac tablet comprises etodolac, a filler, a binder, a disintegrant, a lubricant and a coating material, and the etodolac tablet comprises the following components in percentage by mass:
wherein the filler is one or more of lactose monohydrate, microcrystalline cellulose or corn starch; the adhesive is one or the combination of several of hydroxypropyl cellulose, hydroxypropyl methylcellulose or polyvidone; the disintegrant is one or more of croscarmellose sodium, sodium carboxymethyl starch or calcium carboxymethylcellulose; the lubricant is one or more of talcum powder, magnesium stearate or colloidal silica.
A preparation method of etodolac tablets comprises the following steps: the etodolac tablet is prepared by mixing an etodolac filling agent and an adhesive for granulation, sieving the granules step by step, mixing a disintegrating agent and a lubricating agent, pressing the mixture into tablets, and finishing the coating process by a coating material. In the primary mixing process, setting the stirring speed to be 5r/s, setting the chopping speed to be 20r/s, then mixing for 10min, adding purified water after even mixing, and granulating for 5 min. The sieving process comprises drying the wet granules with 20 mesh sieve, and sieving with 24 mesh sieve to obtain granules with water content of less than 3%.
The present invention will be described in further detail with reference to examples.
Example 1
Prescription:
the preparation method comprises the following steps:
placing etodolac, lactose monohydrate, corn starch and hydroxypropyl cellulose in a wet granulator, setting a stirring speed of 5r/s and a chopping speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, performing wet granulation by using a 20-mesh sieve, drying in an oven until the water content is less than 3%, performing granulation by using a 24-mesh sieve, adding additional auxiliary materials of croscarmellose sodium and magnesium stearate, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, coating by using an opadry aqueous solution (with the solid content of 10%) and increasing the weight by 3.0%.
Example 2
Prescription:
the preparation method comprises the following steps:
placing etodolac, lactose monohydrate and hydroxypropyl methylcellulose into a wet granulator, setting a stirring rotation speed of 5r/s, a chopping rotation speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, sieving with a 20-mesh sieve for wet granulation, drying in an oven until the water content is less than 3%, sieving with a 24-mesh sieve for granulation, adding additional auxiliary materials of carboxymethyl starch sodium and talcum powder, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, and coating by using an opadry solution (with the solid content of 10%) to increase the weight by 4.0%.
Example 3
Prescription:
the preparation method comprises the following steps:
placing etodolac, corn starch and hypromellose in a wet granulator, setting stirring speed at 5r/s, chopping speed at 20r/s, mixing for 10min, adding purified water, granulating for 5min, wet granulating with 20 mesh sieve, oven drying until water content is less than 3%, granulating with 24 mesh sieve, adding additional adjuvants of carboxymethylcellulose calcium and magnesium stearate, mixing for 10min, tabletting, controlling hardness to 8.0-12.0kg, coating with Opadry water solution (solid content is 10%), and increasing weight by 2.0%.
Example 4
Prescription:
the preparation method comprises the following steps:
placing etodolac, microcrystalline cellulose and hydroxypropyl cellulose in a wet granulator, setting a stirring speed of 5r/s and a chopping speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, carrying out wet granulation by using a 20-mesh sieve, drying in an oven until the water content is less than 3%, carrying out granulation by using a 24-mesh sieve, adding additional auxiliary materials of croscarmellose sodium and magnesium stearate, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, coating by using an opadry aqueous solution (with the solid content of 10%) and increasing the weight by 3.0%.
Example 5
Prescription:
the preparation method comprises the following steps:
placing etodolac, microcrystalline cellulose and hydroxypropyl cellulose in a wet granulator, setting a stirring speed of 5r/s and a chopping speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, carrying out wet granulation by using a 20-mesh sieve, drying in an oven until the water content is less than 3%, carrying out granulation by using a 24-mesh sieve, adding additional auxiliary materials of croscarmellose sodium and magnesium stearate, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, coating by using an opadry aqueous solution (with the solid content of 10%) and increasing the weight by 3.5%.
Example 6
Prescription:
the preparation method comprises the following steps:
placing etodolac, microcrystalline cellulose and hydroxypropyl cellulose in a wet granulator, setting a stirring speed of 5r/s and a chopping speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, carrying out wet granulation by using a 20-mesh sieve, drying in an oven until the water content is less than 3%, carrying out granulation by using a 24-mesh sieve, adding additional auxiliary materials of croscarmellose sodium and magnesium stearate, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, coating by using an opadry aqueous solution (with the solid content of 10%) and increasing the weight by 2.4%.
Example 7
Prescription:
the preparation method comprises the following steps:
placing etodolac, microcrystalline cellulose and hydroxypropyl cellulose in a wet granulator, setting a stirring speed of 5r/s and a chopping speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, carrying out wet granulation by using a 20-mesh sieve, drying in an oven until the water content is less than 3%, carrying out granulation by using a 24-mesh sieve, adding additional auxiliary materials of croscarmellose sodium and magnesium stearate, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, coating by using an opadry aqueous solution (with the solid content of 10%) and increasing the weight by 3.1%.
Example 8
Prescription:
the preparation method comprises the following steps:
placing etodolac, microcrystalline cellulose and hydroxypropyl cellulose in a wet granulator, setting a stirring speed of 5r/s and a chopping speed of 20r/s, mixing for 10min, adding purified water for granulation for 5min, carrying out wet granulation by using a 20-mesh sieve, drying in an oven until the water content is less than 3%, carrying out granulation by using a 24-mesh sieve, adding additional auxiliary materials of croscarmellose sodium and magnesium stearate, mixing for 10min, tabletting, controlling the hardness to be 8.0-12.0kg, coating by using an opadry aqueous solution (with the solid content of 10%) and increasing the weight by 2.9%.
Example 9: determination of dissolution curve of etodolac tablets
According to a dissolution and release determination method (0931 second method of the general rule of the four departments in 2020 edition) of etodolac tablets prepared by the method of the embodiment 1-8 of the invention, dissolution curves of self-made samples and commercially available samples of the etodolac tablets are determined, 900ml of phosphate buffer solution (pH 6.8) is used as a solvent, the rotating speed is 50 revolutions per minute, the operation is carried out according to the method, at the 5 th, 10 th, 15 th and 30 th minutes, a proper amount of solution is taken for filtering, after primary filtrate is discarded, a proper amount of subsequent filtrate is precisely taken, and a dissolution medium is added for dilution to prepare a solution containing 22 mug in each 1ml, and the solution is used as a test sample solution; further, 0.02g of a control sample dried under reduced pressure at 60 ℃ for 4 hours was precisely weighed, placed in a 100ml measuring flask, dissolved with 10ml of methanol, diluted with a dissolution medium to a predetermined scale, shaken, and precisely measured in an appropriate amount, diluted with a dissolution medium to give a solution containing 20. mu.g per 1ml, and used as a control solution, and the above solutions were measured for absorbance at a wavelength of 279nm by UV-visible spectrophotometry, and a dissolution curve was plotted as shown in FIG. 1 below.
The dissolution curve detection result shows that the etodolac tablet prepared by the method of the embodiment 4 realizes good fitting with the dissolution curve of a commercial preparation in a medium with pH6.8, and the in-vitro dissolution behaviors of the etodolac tablet and the commercial preparation are most similar, so that the small sample of the embodiment 4 is taken as a main research object in subsequent research.
Example 10: etodolac tablet stability test
And (3) accelerated test: etodolac tablets prepared by the method of embodiment 4 of the invention are placed in a constant temperature and humidity box under the condition of commercial package, placed under the conditions of 40 ℃ plus or minus 2 ℃ and 75% plus or minus 5% of relative humidity, sampled at 1 st, 2 nd, 3 th and 6 th months in time respectively, and detected according to a quality standard draft, and the results are shown in Table 1.
Table 1: accelerated test detection data summary table
And (3) long-term test: etodolac tablets prepared by the method of embodiment 4 of the invention are placed in a constant temperature and humidity box under the condition of commercial package, placed under the conditions of 25 ℃ plus or minus 2 ℃ and 60% plus or minus 5% of relative humidity, sampled at 3 rd, 6 th, 9 th, 12 th and 18 th months in time respectively, and measured according to a quality standard draft. The results of the measurement were compared with the results of the measurement at 0 month, and the results are shown in Table 2.
Table 2: long-term test detection data summary table
The stability examination result shows that after the stability examination of 6 months and 18 months for a long time, the characters, dissolution rates, contents and related substances of the etodolac tablet have no obvious change, which indicates that the stability of the etodolac tablet is good.
Example 11: test of clinical application effect of etodolac tablets
To examine the effect of the present invention in clinical application, we selected 60 naturally occurring pet dogs as experimental animals in a pet hospital, and each dog was randomly divided into 3 groups of 20 dogs each exhibiting associated pain and inflammation caused by osteoarthritis within 7 days. One group was left untreated as a blank control; one group used commercially available etodolac tablets as a treatment control group; the final group used the product of the invention made in example 4 as the test group.
1. Test protocol
The product and the commercial etodolac tablet are both mixed in food of sick dogs for oral administration once a day, the administration dose is 10mg/kg body weight, and the administration lasts for 5 days. The change condition of the disease part of the dog and the physical signs such as the movement behavior are observed before and after the test. The disease condition is judged according to the sign observation results of the sick dog before, on the same day as, 3 days after and 5 days after the administration. The method is divided into a plurality of grades of curing (no disease manifestation), improving (the red and swollen condition of a disease part is relieved, the exercise condition becomes better), no change and more serious (the red and swollen condition of the disease part is aggravated, and the exercise condition is worse).
2. Test results
2.1 blank control group
After the 5 th day, 2 dogs with the blank control group showed some improvement in symptoms, 3 dogs showed no obvious change, and the rest 15 dogs showed more serious symptoms such as aggravated red swelling and worse movement status of the affected parts.
2.2 commercial Etodolac tablet test treatment group
After 3 days of administration, 4 dogs were substantially cured, 6 dogs were improved in symptoms, 9 dogs were not significantly changed, and 1 dog was more severe. After 5 days of administration, 11 dogs were substantially cured, 4 dogs were improved in symptoms, and 5 dogs were not significantly changed.
2.3 test treatment group of products of the invention
After 3 days of administration, 6 dogs were substantially cured, 9 dogs had improved symptoms, and 5 dogs had no significant change. After 5 days of administration, 17 dogs healed and 3 dogs improved symptoms significantly.
The test data were collated and the results are shown in the following table
Test results show that the etodolac tablet provided by the invention is remarkably superior to a commercially available etodolac tablet set in the effects of treating related pain and inflammation caused by osteoarthritis of pet dogs.
The technical scope of the present invention is not limited to the above description, and those skilled in the art can make various changes and modifications to the above-described embodiments without departing from the technical spirit of the present invention, and these changes and modifications should fall within the protective scope of the present invention.
Claims (10)
1. The etodolac tablet is characterized by comprising etodolac, a filler, a binder, a disintegrant, a lubricant and a coating material, wherein the etodolac tablet comprises the following components in percentage by mass:
2. the etodolac tablet of claim 1, wherein the filler is one or a combination of lactose monohydrate, microcrystalline cellulose, or corn starch.
3. The etodolac tablet of claim 1, wherein the binder is one or a combination of hydroxypropyl cellulose, hypromellose, or povidone.
4. An etodolac tablet according to claim 1, wherein the disintegrant is one or a mixture of croscarmellose sodium, sodium carboxymethyl starch or calcium carboxymethylcellulose.
5. The etodolac tablet of claim 1, wherein the lubricant is one or a combination of talc, magnesium stearate, or colloidal silicon dioxide.
6. Etodolac tablets according to claims 1-5, comprising, in mass fraction, 75% Etodolac, 13% microcrystalline cellulose, 5% hydroxypropyl cellulose, 3% croscarmellose sodium, 1% magnesium stearate and 3% Opadry.
7. A method for preparing an etodolac tablet according to claim 6, comprising the steps of: primarily mixing etodolac, a filling agent and an adhesive for granulation, screening the granules step by step, mixing a disintegrating agent and a lubricating agent, pressing the mixture into tablets, and finishing a coating process by using a coating material to obtain the etodolac tablets.
8. A preparation method of etodolac tablets according to claim 7, wherein in the primary mixing process, the stirring speed is set to be 5r/s, the chopping speed is set to be 20r/s, then the mixture is mixed for 10min, and after the uniform mixing, purified water is added for granulation for 5 min.
9. A process for preparing etodolac tablet according to claim 8, wherein the sieving process is specifically as follows, the drying process is carried out after wet and whole granules are sieved with a 20 mesh sieve, and the whole granules are sieved with a 24 mesh sieve, and the moisture content is less than 3%.
10. The method for preparing an etodolac tablet according to claim 9, wherein the etodolac tablet has a hardness of 8-12 kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111617427.2A CN114699380A (en) | 2021-12-27 | 2021-12-27 | Etodolac tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111617427.2A CN114699380A (en) | 2021-12-27 | 2021-12-27 | Etodolac tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114699380A true CN114699380A (en) | 2022-07-05 |
Family
ID=82166679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111617427.2A Pending CN114699380A (en) | 2021-12-27 | 2021-12-27 | Etodolac tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114699380A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| WO2001019349A2 (en) * | 1999-09-10 | 2001-03-22 | Ranbaxy Laboratories Limited | Extended release formulation of etodolac |
| CN101259113A (en) * | 2008-04-21 | 2008-09-10 | 沈阳药科大学 | Etodolac osmotic pump type controlled-release preparation and preparation thereof |
| CN102485215A (en) * | 2010-12-03 | 2012-06-06 | 沈阳药科大学 | Etodolac timed-release pellet and preparation method thereof |
| WO2012173581A1 (en) * | 2011-03-21 | 2012-12-20 | Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. | Thiocolchicoside, etodolac and famotidine combinations |
| WO2013169218A1 (en) * | 2012-05-08 | 2013-11-14 | Mahmut Bilgic | Pharmaceutical compositions of s-etodolac |
| CN104257625A (en) * | 2014-09-26 | 2015-01-07 | 山东新时代药业有限公司 | Etodolac capsule and preparation method thereof |
| WO2018004498A1 (en) * | 2016-06-30 | 2018-01-04 | Imuneks Farma Ilac San. Ve Tic. A.S. | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation |
| WO2019135725A1 (en) * | 2018-01-03 | 2019-07-11 | Pisak Mehmet Nevzat | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation |
-
2021
- 2021-12-27 CN CN202111617427.2A patent/CN114699380A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| WO2001019349A2 (en) * | 1999-09-10 | 2001-03-22 | Ranbaxy Laboratories Limited | Extended release formulation of etodolac |
| CN101259113A (en) * | 2008-04-21 | 2008-09-10 | 沈阳药科大学 | Etodolac osmotic pump type controlled-release preparation and preparation thereof |
| CN102485215A (en) * | 2010-12-03 | 2012-06-06 | 沈阳药科大学 | Etodolac timed-release pellet and preparation method thereof |
| WO2012173581A1 (en) * | 2011-03-21 | 2012-12-20 | Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. | Thiocolchicoside, etodolac and famotidine combinations |
| WO2013169218A1 (en) * | 2012-05-08 | 2013-11-14 | Mahmut Bilgic | Pharmaceutical compositions of s-etodolac |
| CN104257625A (en) * | 2014-09-26 | 2015-01-07 | 山东新时代药业有限公司 | Etodolac capsule and preparation method thereof |
| WO2018004498A1 (en) * | 2016-06-30 | 2018-01-04 | Imuneks Farma Ilac San. Ve Tic. A.S. | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation |
| WO2019135725A1 (en) * | 2018-01-03 | 2019-07-11 | Pisak Mehmet Nevzat | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI778983B (en) | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| US4950484A (en) | Pharmaceutical tablet, pharmaceutical granulate and process for their preparation | |
| US8303868B2 (en) | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose | |
| NO138683B (en) | BASIC FOR USE IN THE PREPARATION OF A PHARMACEUTICAL PREPARATION WITH SLOW RELEASE OF THE ACTIVE INGREDIENT | |
| WO2020249001A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| KR20040005986A (en) | Solid Pharmaceutical Formulations Comprising Modafinil | |
| US20170095507A1 (en) | Dispersion preparation containing colloidal bismuth pectin and preparing method therefor | |
| TWI418370B (en) | Dissolution-stable pharmaceutical agent | |
| CN113058038B (en) | Solid preparation containing tolagliflozin and production method thereof | |
| KR101485421B1 (en) | Controlled-release Oral Drug Preparations and it's Manufacturing Process Containing Itopride Hydrochloride | |
| KR20160002177A (en) | Pharmaceutical composition comprising oseltamivir free base | |
| CN114699380A (en) | Etodolac tablet and preparation method thereof | |
| CN115429770B (en) | Mo Nuola-Weather pharmaceutical composition with good stability and preparation method thereof | |
| CN108324697B (en) | Mosapride citrate-containing capsule and preparation method thereof | |
| WO2010137716A1 (en) | Orally disintegrating tablet which contains precipitated calcium carbonate as active ingredient | |
| CN112057427B (en) | Oral solid tablet containing bruton's tyrosine kinase inhibitor and preparation method thereof | |
| KR102102462B1 (en) | Pharmaceutical composition comprising oseltamivir free base | |
| CN114699374B (en) | Fluoxetine hydrochloride solid preparation special for dogs and cats and preparation and application thereof | |
| EA015519B1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
| CN112263569B (en) | Amoxicillin capsule and preparation method thereof | |
| CN112057429A (en) | Controlled release pharmaceutical compositions of rasinades | |
| CN116173039B (en) | Pharmaceutical composition for treating irritable bowel syndrome and preparation method thereof | |
| CN114306259B (en) | Sodium valproate double-layer sustained release tablet and preparation method thereof | |
| CN112618502B (en) | High-dissolution clotrimazole vaginal tablet and preparation process thereof | |
| CN117731627A (en) | Dopa hydrazine tablet and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220705 |
|
| RJ01 | Rejection of invention patent application after publication |